The Effects of Linezolid and Vancomycin on Inflammation and Cellular Signaling Vents
We will determine if linezolid inhibits cellular activation and production of pro-inflammatory cytokines, providing mechanistic rationale for its clinical efficacy and the justification for further investigations in S. Aureus sepsis.
|Study Design:||Time Perspective: Prospective|
|Official Title:||The Effects of Linezolid and Vancomycin on Inflammation and Cellular Signaling Vents|
- IL-6 [ Time Frame: 12 Months ] [ Designated as safety issue: No ]Measurement of IL-6 release in response to MRSA.
- MCP-1 [ Time Frame: 12 Months ] [ Designated as safety issue: No ]Measurement of MCP-1 release in response to MRSA.
Biospecimen Retention: Samples Without DNA
|Study Start Date:||January 2009|
|Study Completion Date:||June 2010|
|Primary Completion Date:||June 2010 (Final data collection date for primary outcome measure)|
Drug: Linezolid or Vancomycin
Whole blood samples from healthy subjects will be incubated with MRSA bacterium or bacterial toxins in the presence and absence of either linezolid or vancomycin. Final concentrations will mimic physiologic conditions. Platelets and leukocytes will be isolated and assayed for the presence of absence of activation and pre-mRNA splicing.
Other Name: Zyvox
Please refer to this study by its ClinicalTrials.gov identifier: NCT00811980
|Principal Investigator:||Guy Zimmerman, MD||University of Utah|